• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

Recent Advances in the Study of Cyclopropanamine, 2-fluoro-, (1S-cis)- (CAS: 149404-98-8)

The compound Cyclopropanamine, 2-fluoro-, (1S-cis)- (CAS: 149404-98-8) has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This chiral cyclopropane derivative, characterized by its unique fluorine substitution and stereochemistry, has been explored for its role as a building block in the synthesis of bioactive molecules. Recent studies have highlighted its utility in the design of enzyme inhibitors, receptor modulators, and other pharmacologically active compounds.

One of the key areas of research involving Cyclopropanamine, 2-fluoro-, (1S-cis)- is its incorporation into small-molecule therapeutics targeting central nervous system (CNS) disorders. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a precursor in the synthesis of novel GABA_A receptor modulators. The study reported that the fluorine atom and the rigid cyclopropane ring enhance binding affinity and metabolic stability, making it a promising candidate for the treatment of anxiety and epilepsy.

In addition to CNS applications, recent investigations have explored the compound's role in oncology. A preprint article from BioRxiv (2024) detailed its use in the development of covalent inhibitors targeting mutant KRAS proteins, which are implicated in various cancers. The researchers utilized the (1S-cis) configuration to achieve selective binding to the oncogenic protein, resulting in potent antitumor activity in preclinical models. This finding underscores the compound's versatility in addressing unmet medical needs in oncology.

From a synthetic chemistry perspective, advancements in the asymmetric synthesis of Cyclopropanamine, 2-fluoro-, (1S-cis)- have been reported. A 2023 paper in Organic Letters described a catalytic enantioselective method using chiral palladium complexes, achieving high yields and enantiomeric excess (>99%). This methodological breakthrough is expected to facilitate broader access to the compound for research and industrial applications.

Despite these promising developments, challenges remain in the large-scale production and formulation of Cyclopropanamine, 2-fluoro-, (1S-cis)-. Stability studies indicate that the compound is sensitive to light and moisture, necessitating specialized handling and storage conditions. Ongoing research aims to address these limitations through the development of prodrug strategies and advanced delivery systems.

In conclusion, Cyclopropanamine, 2-fluoro-, (1S-cis)- (CAS: 149404-98-8) represents a valuable scaffold in modern drug discovery. Its unique structural features and demonstrated biological activities make it a focal point for interdisciplinary research. Future studies are likely to explore its applications in additional therapeutic areas, further solidifying its importance in the field of chemical biology and pharmaceutical sciences.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)